華東醫藥(000963.SZ)子公司兩個產品新納入國家醫保藥品目錄
格隆匯8月21日丨華東醫藥(000963.SZ)公佈,近日,根據國家醫保局、人力資源社會保障部正式發佈的《關於印發
<國家基本醫療保險、工傷保險和生育保險藥品目錄>
的通知》【醫保發〔2019〕46號】(以下簡稱《藥品目錄》),公司全資子公司杭州中美華東製藥有限公司(“中美華東”)有1個產品新納入《藥品目錄》,公司全資子公司華東醫藥(西安)博華製藥有限公司(“西安博華”)有1個產品新納入《藥品目錄》。
國家基本醫療保險、工傷保險和生育保險藥品目錄>
上述新納入該目錄的兩個產品均屬於醫保乙類品種,正常生產銷售。中美華東、西安博華及控股子公司陝西九州製藥有限責任公司等公司原納入2017版《藥品目錄》的產品本次均繼續納入《藥品目錄》。
此外,公司目前正處於研發階段的多個品種也納入《藥品目錄》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.